Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.

Hunter, E, et. al.,
The Lancet Neurology Conference

Epigenetic signatures and early detection of neurodegenerative diseases.

Salter, M., et. al.,
The Lancet Neurology Conference

Chromosome conformation capture to discover candidate epigenetic markers of Multiple Sclerosis disease severity.

Sangurdekar, D., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Epigenetic profile of chromosome conformation signatures underlying multiple sclerosis and its severity.

Joesph, JP., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment and Trials.

Jeznach, M.
International Pharmaceutical Industry

Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients.

Carini, C., et. al.,
Annual Meeting of the American College of Rheumatology

Development of Epigenetic Profiling of ALS Patients with Chromosome Conformation Biomarkers Offers Novel Signatures for Non-invasive Diagnostic and Prognostic Stratifications.

Hunter, E., et. al.,
14th Annual Northeast Amyotrophic Lateral Sclerosis Consortium

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.

Jakub, JW., et. al.,
Melanoma Research

Chromatin barcodes as biomarkers for melanoma.

Bastonini, E., et. al.,
Pigment Cell Melanoma Research

A blood-based epigenetic test for early detection of hepatocellular carcinoma (HCC).

Lim, EH., et. al.,
J Clinical Oncology